Orthovita to Market Medafor's MPH® Hemostatic Technology Under the Name VITASURE™.
MINNEAPOLIS, April 27, 2008 - Medafor is pleased to announce that it has signed a non-exclusive agreement with Orthovita, Inc., Philadelphia, Penna., to distribute Medafor's patented MPH® polysaccharide hemostatic technology under the private label VITASURE™. READ FULL STORY.

CryoLife Signs Exclusive Agreement to Distribute Medafor's MPH® Technology
MINNEAPOLIS, April 25, 2008 - Medafor is pleased to announce that it has signed an exclusive agreement with CryoLife, Inc., Atlanta, Ga., to distribute Medafor's patented MPH(r) polysaccharide hemostatic technology under the private label Hemostase MPH beginning May 1, 2008. READ FULL STORY.

FDA Lifts Urological Surgical Restriction for Medafor’s Arista™AH Absorbable Surgical Hemostat
MINNEAPOLIS, July 16, 2007 -- Medafor, Inc., announced today that its Arista™AH Absorbable Hemostat is now available for use in urological surgical procedures. The FDA has removed the restriction on this application of Arista AH from the device indication statement. READ FULL STORY.

FDA Approves Medafor's Arista™AH Absorbable Surgical Hemostat for U.S. Operating Rooms
MINNEAPOLIS, October 3, 2006 -- Medafor, Inc., announced today that its Arista™ AH Absorbable Hemostat has received FDA approval to be marketed within the United States. Arista AH has been distributed internationally since 2002 and has compiled a remarkable record of surgical success around the world. In the U.S., this easy-to-use, efficacious and safe hemostat is indicated for most types of surgery including cardiac, orthopedic, spinal and general surgical applications. READ FULL STORY.